The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
Open accessAbstract
DNA and RNA stimulate the mammalian innate immune system through activation of Toll-like receptors (TLRs). DNA containing methylated CpG motifs, however, is not stimulatory. Selected nucleosides in naturally occurring RNA are also methylated or otherwise modified, but the immunomodulatory effects of these alterations remain untested. We show that RNA signals through human TLR3, TLR7, and TLR8, but incorporation of modified nucleosides m5C, m6A, m5U, s2U, or pseudouridine ablates activity. Dendritic cells (DCs) exposed to such modified RNA express significantly less cytokines and activation markers than those treated with unmodified RNA. DCs and TLR-expressing cells are potently activated by bacterial and mitochondrial RNA, but not by mammalian total RNA, which is abundant in modified nucleosides. We conclude that nucleoside modifications suppress the potential of RNA to activate DCs. The innate immune system may therefore detect RNA lacking nucleoside modification as a means of selectively responding to bacteria or necrotic tissue.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“which is widely believed to be critical to the recent success of mRNA vaccines1,2,10,37,38”
From Algorithm for optimized mRNA design improves stability and immunogenicity (2023) · cites this paper as [37]
In the citing paper
“Modifications to the spike protein are intended to reduce the innate immune response by inhibiting proinflammatory cytokines, while at the same time, the lipid nanoparticle vehicle/EV for the mRNA acts as an adjuvant to enhance the immune response. 194-196”
From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [194]
In the citing paper
“In general, in vitro transcribed mRNA has the risk of triggering various pattern recognition receptors in the endosome (e.g., TLR7/8) or the cytoplasm (e.g., RIG-I), which lead to an anti-viral response, followed by a shutdown of translation that can lower expression of the mRNA-encoded protein.25”
From Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines (2017) · cites this paper as [25]
In the citing paper
“Transferring this concept to in vitro transcribed mRNA, for instance, pseudouridine-containing mRNAs reduced activation of known RNA sensors substantially.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [20]
In the citing paper
“Obviously, cytokine secretion by RNA-transfected cells strongly correlated with the extent of nucleoside modifications.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [20]
In the citing paper
“In addition, nucleoside modifications are well known to limit or even inhibit RNA sensor engagement.20,21,22”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [20]
In the citing paper
“Others strategies aim to impair the PRR recognition of IVT mRNA with the use of modified nucleosides,16 uridine depletion in the coding sequence,17 or dephosphorylation of 5′PPP mRNAs.18”
From Combining an optimized mRNA template with a double purification process allows strong expression of in vitro transcribed mRNA (2021) · cites this paper as [16]
In the citing paper
“In particular, we focused on ψ and m1ψ, since these substitutions for U have been widely adopted for mRNA therapeutics and vaccines due to improved in-cell translation and to better control of innate immune responses2,3,8,67 through avoidance of recognition by cellular toll-like receptors (TLR7 and TLR8)68, RIG‑I, and PKR69–71.”
From Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics (2022) · cites this paper as [70]
In the citing paper
“Studies have found that replacing original nucleosides with m6A and s2U inhibits activation of TLR3, whereas activation of TLR7 and TLR8 is blocked when using ψ, 5-methyluridine (m5U), m6A, and s2U, thereby inhibiting the innate immune responses and improving protein translation efficiency.81,159,171”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [81]
In the citing paper
“Nucleoside-modified mRNA can reduce the activation of TLRs, retinoic acid-inducible gene I (RIG-I), protein kinase R (PKR), and 2′-5′-oligoadenylate synthetase (OAS). Additionally, nucleoside modification increases translation activity and resistance against RNase L-mediated degradation.54,81,173–176”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [81]
In the citing paper
“To avoid this, Karikó and colleagues found that adding modified nucleosides during IVT of mRNA can significantly reduce the host inflammatory response without affecting protein expression.81,159”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [81]
In the citing paper
“However, the incorporation of modified nucleosides into mRNA can significantly improve the biological stability and translational capacity of the mRNA while decreasing the innate immune response.36, 37, 38”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [36]
In the citing paper
“not only viral RNA, but also endogenous mRNA associated with apoptotic cells as well as in vitro transcribed (IVT) mRNA could bind and activate TLR3, TLR7 and TLR8 [4,5]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [5]
In the citing paper
“the many modifications observed in natural mRNA are in fact a way to avoid immune recognition, allowing the immune system to distinguish self from non-self RNA [5]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [5]
In the citing paper
“Chemical modifications of specific IVT mRNA nucleotides, such as pseudouridine (ψ) and N1-methylpseudouridine (m1ψ), can reduce innate immune sensing of exogenous mRNA translation2,4,7,182.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [182]
In the citing paper
“In 2004, Karikó and colleagues observed, while exposing ex vivo human DCs to mRNA from different sources, that these cells tolerated mammalian mRNA, while strong inflammatory cytokine responses were detected upon the delivery of mRNA derived from bacteria, necrotic mammalian cells and IVT mRNA [39,40].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [39]
Citations
Cites
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 3×
“To determine whether m5C and m6A evidence, first that bacterial RNA transfected to 293-exert a dominant stimulatory effect, transcripts with hTLR9 did not induce IL-8 secretion (Figure 2C) and m6A/ Ψ double modification were tested and found to second that LPS and unmethylated DNA (CpG ODN), be nonstimulatory, whereas…”
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Toll-like receptors and innate immunity
Medzhitov, R. (2001) · Nature Reviews Immunology · doi:10.1038/35100529 · Cited by 4,308
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis
Wang, T., Town, T., Alexopoulou, L., Anderson, J. F., Fikrig, E., & Flavell, R. A. (2004) · Nature Medicine · doi:10.1038/nm1140 · Cited by 1,142
mRNA is an endogenous ligand for toll-like receptor 3
Karikó, K., Ni, H., Capodici, J., Lamphier, M., & Weissman, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310175200 · Cited by 1,062
Self-citationHuman TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848
Jurk, M., Heil, F., Vollmer, J., Schetter, C., Krieg, A. M., Wagner, H., Lipford, G., & Bauer, S. (2002) · Nature Immunology · doi:10.1038/ni0602-499 · Cited by 838
Subcellular Localization of Toll-Like Receptor 3 in Human Dendritic Cells
Matsumoto, M., Funami, K., Tanabe, M., Oshiumi, H., Shingai, M., Seto, Y., Yamamoto, A., & Seya, T. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.6.3154 · Cited by 723
Santini, S. M., Lapenta, C., Logozzi, M., Parlato, S., Spada, M., Pucchio, T. D., & Belardelli, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.10.1777 · Cited by 644
Cited by
Sorted by citations
Items 901–1,000 of 1,004
What goes around comes around: Artificial circular RNAs bypass cellular antiviral responses
Breuer, J., Barth, P., Noe, Y., Shalamova, L. A., Goesmann, A., Weber, F., & Roßbach, O. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.04.017 · Cited by 35
Synthesis of point-modified mRNA
Hertler, J., Slama, K., Schober, B., Özrendeci, Z., Marchand, V., Motorin, Y., & Helm, M. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac719 · Cited by 35
Myocarditis associated with COVID-19 and its vaccines - a systematic review
Rout, A., Suri, S. S., Vorla, M., & Kalra, D. K. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.10.004 · Cited by 38
The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections
You, H., Jones, M. K., Gordon, C. A., Arganda, A. E., Cai, P., Al-Wassiti, H., Pouton, C. W., & McManus, D. P. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00241-21 · Cited by 39
Yim, E. Y., Zhou, A. C., Yim, Y. C., Wang, X., & Xia, T. (2023) · BMEMat · doi:10.1002/bmm2.12060 · Cited by 35
Beyond Double-Stranded RNA-Type I IFN Induction by 3pRNA and Other Viral Nucleic Acids
Schlee, M., Barchet, W., Hornung, V., & Hartmann, G. (2007) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-71329-6_11 · Cited by 34
Achieving efficient RNAi therapy: progress and challenges
Gao, K., & Huang, L. (2013) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2013.06.005 · Cited by 34
Lichtnekert, J., Vielhauer, V., Zecher, D., Kulkarni, O. P., Clauß, S., Segerer, S., Hornung, V., Mayadas, T. N., Beutler, B., Akira, S., et al. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90213.2008 · Cited by 34
Okuyama, R. (2023) · Vaccines · doi:10.3390/vaccines11121737 · Cited by 38
Advances and prospects of mRNA vaccines in cancer immunotherapy
Liu, Y., Yan, Q., Zeng, Z., Fan, C., & Xiong, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189068 · Cited by 33
RNA pulsed dendritic cells: An approach for cancer immunotherapy
Garg, N. K., Dwivedi, P., Prabha, P. S., & Tyagi, R. K. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.12.027 · Cited by 35
Base Modification Strategies to Modulate Immune Stimulation by an siRNA
Valenzuela, R., Suter, S. R., Ball‐Jones, A. A., Ibarra‐Soza, J. M., Zheng, Y., & Beal, P. A. (2014) · ChemBioChem · doi:10.1002/cbic.201402551 · Cited by 33
Methylated DNA/RNA in Body Fluids as Biomarkers for Lung Cancer
Lu, Y., Li, S. S., Zhu, S., Gong, Y., Shi, J., & Xu, L. (2017) · Biological Procedures Online · doi:10.1186/s12575-017-0051-8 · Cited by 34
Keller, P., Freund, I., Marchand, V., Bec, G., Huang, R., Motorin, Y., Eigenbrod, T., Dalpke, A. H., & Helm, M. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky644 · Cited by 33
Nakanishi, H., & Saito, H. (2020) · Nature Communications · doi:10.1038/s41467-020-15061-x · Cited by 32
What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021
Yoo, J. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e54 · Cited by 33
Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines
Abbasi, S., & Uchida, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050644 · Cited by 33
Morris, G., & Schorge, S. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.03.010 · Cited by 36
Kazzi, P. E., Rabah, N., Chamontin, C., Poulain, L., Ferrón, F., Debart, F., Canard, B., Missé, D., Coutard, B., Nisole, S., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac996 · Cited by 33
RNAi as a new therapeutic strategy against HCV
Khaliq, S., Khaliq, S. A., Zahur, M., Ijaz, B., Jahan, S., Ansar, M., Riazuddin, S. A., & Hassan, S. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.08.004 · Cited by 35
Tsuda, N., Chang, D. Z., Mine, T., Efferson, C. L., García‐Sastre, A., Wang, X., Ferrone, S., & Ioannides, C. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0327 · Cited by 33
mRNA Synthesis and Encapsulation in Ionizable Lipid Nanoparticles
McKenzie, R. E., Minnell, J. J., Ganley, M., Painter, G. F., & Draper, S. L. (2023) · Current Protocols · doi:10.1002/cpz1.898 · Cited by 38
Selection on synonymous sites: the unwanted transcript hypothesis
Radrizzani, S., Kudla, G., Izsvák, Z., & Hurst, L. D. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-023-00686-7 · Cited by 34
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends
Gao, Y., Yang, L., Li, Z., Peng, X., & Li, H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00644-3 · Cited by 34
Makhamreh, A. K., Tavakoli, S., Fallahi, A., Kang, X., Gamper, H., Nabizadehmashhadtoroghi, M., Jain, M., Hou, Y., Rouhanifard, S. H., & Wanunu, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-72994-9 · Cited by 32
Laila, U. E., An, W., & Xu, Z.-X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1448489 · Cited by 34
Current Non-Viral-Based Strategies to Manufacture CAR-T Cells
Gehrke, L., Gonçalves, V. D. R., Andrae, D., Raskó, T., Ho, P., Einsele, H., Hudecek, M., & Friedel, S. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413685 · Cited by 34
Qdaisat, S., Wummer, B. M., Stover, B. D., Zhang, D., McGuiness, J., Weidert, F. L., Chardon‐Robles, J., Grippin, A., DeVries, A., Zhao, C., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01380-1 · Cited by 42
Inoüe, R., Nagino, T., Hoshino, G., & Ushida, K. (2010) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2010.00752.x · Cited by 32
Cardiovascular regenerative therapeutics via synthetic paracrine factor modified mRNA
Lui, K. O., Zangi, L., & Chien, K. R. (2014) · Stem Cell Research · doi:10.1016/j.scr.2014.06.007 · Cited by 32
Pros and cons of pDNA and mRNA transfection to study mRNA translation in mammalian cells
Andreev, D. E., Terenin, I. M., Dmitriev, S. E., & Shatsky, I. N. (2015) · Gene · doi:10.1016/j.gene.2015.12.008 · Cited by 32
RNA Methylation in Systemic Lupus Erythematosus
Lv, X., Liu, X., Zhao, M., Wu, H., Zhang, W., Lu, Q., & Chen, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.696559 · Cited by 31
Wang, A. Y. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158148 · Cited by 34
Impact of N6-methyladenosine (m6A) modification on immunity
Elsabbagh, R. A., Rady, M., Watzl, C., Abou‐Aisha, K., & Gad, M. Z. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00939-8 · Cited by 33
Berdis, A. J. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.1051525 · Cited by 31
Chung, C. W., Kudchodkar, S. B., Chung, C. N., Park, Y. K., Xu, Z., Pardi, N., Abdel‐Mohsen, M., & Muthumani, K. (2023) · Antibodies · doi:10.3390/antib12030046 · Cited by 36
Bioinspired Spatiotemporal Management toward RNA Therapies
Ma, Y., Li, S., Lin, X., & Chen, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c08219 · Cited by 32
Differential tissue targeting of autoimmunity manifestations by Autoantigen‐Associated Y RNAs
Greidinger, E. L., Zang, Y., Martinez, L., Jaimes, K. F., Nassiri, M., Bejarano, P. A., Barber, G. N., & Hoffman, R. W. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22601 · Cited by 32
Li, Y.-P., Xia, R.-X., Wang, H., Li, X., Liu, Y., Wei, Z., Lu, C. C., & Xiang, Z. (2009) · International Journal of Biological Sciences · doi:10.7150/ijbs.5.451 · Cited by 32
Engineering Small Interfering RNAs by Strategic Chemical Modification
Bramsen, J. B., & Kjems, J. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-119-6_5 · Cited by 32
Datta, S. (2020) · ChemRxiv · doi:10.26434/chemrxiv.13102877 · Cited by 31
Toward low-cost gene therapy: mRNA-based therapeutics for treatment of inherited retinal diseases
Antas, P., Carvalho, C., Cabral-Teixeira, J., de Lemos, L., & Seabra, M. C. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.11.009 · Cited by 34
Engineering CAR-T therapies for autoimmune disease and beyond
English, E. P., Swingler, R. N., Patwa, S., Tosun, M., Howard, J. F., Miljković, M. D., & Jewell, C. M. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ado2084 · Cited by 35
Kong, K., Li, B., Chang, Y., Zhao, C., Qiao, H., Jin, M., Wu, X., Fan, W., Wang, L., Qi, Y., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03103-9 · Cited by 31
Eigenbrod, T., Franchi, L., Muñoz-Planillo, R., Kirschning, C. J., Freudenberg, M. A., Núñez, G., & Dalpke, A. H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103258 · Cited by 30
Exosome-Derived miRNAs and Cellular miRNAs Activate Innate Immunity
Mobergslien, A., & Sioud, M. (2013) · Journal of Innate Immunity · doi:10.1159/000351460 · Cited by 31
Sadik, C. D., Bachmann, M., Pfeilschifter, J. M., & Mühl, H. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp525 · Cited by 31
Aptamer–siRNA Chimeras for HIV
Takahashi, M. M., Burnett, J., & Rossi, J. J. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-2432-5_11 · Cited by 31
mRNA-Based Vaccines and Mode of Action
Gergen, J., & Petsch, B. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_230 · Cited by 36
Rahman, M. M., Zhou, N., & Huang, J. (2021) · Vaccines · doi:10.3390/vaccines9030244 · Cited by 32
Campos, C. M., Tsai, K., Courtney, D., Bogerd, H. P., Holley, C. L., & Cullen, B. R. (2021) · RNA · doi:10.1261/rna.078940.121 · Cited by 30
Fang, C., & Liu, C. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1965987 · Cited by 30
RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants
Liang, Q., Wang, Y., Zhang, S., Sun, J., Sun, W., Li, J., Liu, Y., Li, M., Cheng, L., Jiang, Y., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104043 · Cited by 31
Mitochondrial RNA stimulates beige adipocyte development in young mice
Hoang, A. C., Yu, H., Lin, Y., Chen, J.-C., Chen, C., Diedrich, V., Herwig, A., Landgraf, K., Körner, A., & Rőszer, T. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00683-w · Cited by 33
Bai, S., Yang, T., Zhu, C., Feng, M., Zhang, L., Zhang, Z., Wang, X., Yu, R., Pan, X., Chen, Z., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1099991 · Cited by 31
Development of mRNA Vaccines/Therapeutics and Their Delivery System
Son, S., & Lee, K. (2023) · Molecules and Cells · doi:10.14348/molcells.2023.2165 · Cited by 31
ETV2/ER71, the key factor leading the paths to vascular regeneration and angiogenic reprogramming
Kim, T. M., Lee, R. H., Kim, M. S., Lewis, C. A., & Park, C. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03267-x · Cited by 32
Development of gene therapy for treatment of age‐related macular degeneration
Askou, A. L. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12452 · Cited by 32
Lentiviral Vector-Mediated RNA Silencing in the Central Nervous System
Hutson, T. H., Foster, E., Moon, L. D. F., & Yáñez‐Muñoz, R. J. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.016 · Cited by 32
A modified dinucleotide motif specifies tRNA recognition by TLR7
Kaiser, S., Rimbach, K., Eigenbrod, T., Dalpke, A. H., & Helm, M. (2014) · RNA · doi:10.1261/rna.044024.113 · Cited by 31
Russick, J., Delignat, S., Milanov, P., Christophe, O. D., Boros, G., Denis, C. V., Lenting, P. J., Kaveri, S. V., & Lacroix‐Desmazes, S. (2019) · Haematologica · doi:10.3324/haematol.2018.210583 · Cited by 31
Pioneers of mRNA COVID vaccines win medicine Nobel
Callaway, E., & Naddaf, M. (2023) · Nature · doi:10.1038/d41586-023-03046-x · Cited by 31
COVID-19 and Myocarditis: Review of Clinical Presentations, Pathogenesis and Management
Lovell, J. P., Division of Cardiology, D. O. M., Čiháková, D., Department of Pathology, J. H. U. O. M., W. Harry Feinstone Department of Molecular Microbiology and Immunology, J. H. U. B. S. O. P. H., Gilotra, N. A., & Division of Cardiology, D. O. M. (2022) · Heart International · doi:10.17925/hi.2022.16.1.20 · Cited by 29
Vos, J. D., Morreel, K., Alvarez, P., Vanluchene, H., Vankeirsbilck, R., Sandra, P. J. F., & Sandra, K. (2024) · Journal of Chromatography A · doi:10.1016/j.chroma.2024.464756 · Cited by 30
Targeting Accessories to the Crime: Nanoparticle Nucleic Acid Delivery to the Tumor Microenvironment
Harrison, E. B., Azam, S. H., & Pecot, C. V. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00307 · Cited by 31
Nucleotide Modification Alters MicroRNA-Dependent Silencing of MicroRNA Switches
Lockhart, J. H., Canfield, J., Mong, E. F., VanWye, J., & Totary-Jain, H. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.12.007 · Cited by 30
Tajbakhsh, A., Rezaee, M., Barreto, G. E., Moallem, S. A., Henney, N. C., & Sahebkar, A. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106134 · Cited by 30
Modified uridines are the key to a successful message
Karikó, K. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00608-w · Cited by 31
Self-citationMyocarditis following COVID-19 vaccination: incidence, mechanisms, and clinical considerations
Power, J. R., Keyt, L. K., & ADLER, E. D. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2066522 · Cited by 32
Nallagatla, S. R., Jones, C. N., Ghosh, S., Sharma, S. D., Cameron, C. E., Spremulli, L. L., & Bevilacqua, P. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057905 · Cited by 30
mRNAs encoding self-DNA reactive cGAS enhance the immunogenicity of lipid nanoparticle vaccines
Zhivaki, D., Gosselin, E. A., Sengupta, D., Concepcion, H. A., Arinze, C., Chow, J., Nikiforov, A., Komoroski, V., MacFarlane, C., Sullivan, C., et al. (2023) · mBio · doi:10.1128/mbio.02506-23 · Cited by 31
Charting the epitranscriptomic landscape across RNA biotypes using native RNA nanopore sequencing
Diensthuber, G., & Novoa, E. M. (2025) · Molecular Cell · doi:10.1016/j.molcel.2024.12.014 · Cited by 28
Toll-Like Receptor 3: Involvement with Exogenous and Endogenous RNA
Amarante, M. K., & Watanabe, M. A. E. (2010) · International Reviews of Immunology · doi:10.3109/08830185.2010.525723 · Cited by 29
The notorious R.N.A. in the spotlight - drug or target for the treatment of disease
Reautschnig, P., Vogel, P., & Stafforst, T. (2016) · RNA Biology · doi:10.1080/15476286.2016.1208323 · Cited by 30
Real, C. I., Werner, M., Paul, A., Gerken, G., Schlaak, J., Vaillant, A., & Broering, R. (2017) · Scientific Reports · doi:10.1038/srep43838 · Cited by 29
Animal Models for Dengue and Zika Vaccine Development
dos Santos, E. A., & Fink, K. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-8727-1_16 · Cited by 29
Methylation of RNA N6-methyladenosine in modulation of cytokine responses and tumorigenesis
Chang, G., Leu, J.-S., Ma, L., Xie, K., & Huang, S. (2018) · Cytokine · doi:10.1016/j.cyto.2018.06.018 · Cited by 30
Epigenetic regulation in antiviral innate immunity
Wang, X., Xia, H., Liu, S., Cao, L., & You, F. (2021) · European Journal of Immunology · doi:10.1002/eji.202048975 · Cited by 29
Chen, B., Chen, Y., Li, J., Wang, C., Song, W., Wen, Y., Lin, J., Wu, Y., & Ying, T. (2022) · mBio · doi:10.1128/mbio.01612-22 · Cited by 33
Liu, H., Zheng, J., & Liao, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.988130 · Cited by 31
mRNA vaccines: A novel weapon to control infectious diseases
Tian, Y., Deng, Z., & Yang, P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1008684 · Cited by 29
Ocampo, S. M., Romero, C., Aviñó, A. M., Burgueño, J. F., Gassull, M. A., Bermúdez, J., Eritja, R., Fernández, E., & Perales, J. C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.236 · Cited by 29
NIPBL Controls RNA Biogenesis to Prevent Activation of the Stress Kinase PKR
Yuen, K. C. Y., Xu, B., Krantz, I. D., & Gerton, J. L. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.12.012 · Cited by 29
Leyman, B., Huysmans, H., Cafferty, S. M., Combes, F., Cox, E., Devriendt, B., & Sanders, N. N. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00722 · Cited by 30
Targeting Recycling Endosomes to Potentiate mRNA Lipid Nanoparticles
Shin, J., Douglas, C. J., Zhang, S., Seath, C. P., & Bao, H. (2024) · Nano Letters · doi:10.1021/acs.nanolett.3c04415 · Cited by 30
Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders
Arjunan, P., Kathirvelu, D., Mahalingam, G., Goel, A., Zacharaiah, U. G., Srivastava, A., & Marepally, S. K. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.015 · Cited by 33
Leveraging mRNA technology for antigen based immuno-oncology therapies
Floudas, C. S., Sarkizova, S., Ceccarelli, M., & Zheng, W. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010569 · Cited by 32
RNA modifications and their role in gene expression
Artika, I. M., Arianti, R., Demény, M. Á., & Kristóf, E. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1537861 · Cited by 31
Considerations for mRNA Product Development, Regulation and Deployment Across the Lifecycle
Skerritt, J. H. (2025) · Vaccines · doi:10.3390/vaccines13050473 · Cited by 31
Toward an Understanding of Extracellular tRNA Biology
Torres, A. G., & Martı́, E. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.662620 · Cited by 27
Epitranscriptomics of SARS-CoV-2 Infection
Izadpanah, A., Rappaport, J., & Datta, P. K. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.849298 · Cited by 28
Utilization and Potential of RNA-Based Therapies in Cardiovascular Disease
Robinson, E. L., & Port, J. D. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2022.02.003 · Cited by 29
Liu, C., Zhu, J., Mi, Y., & Jin, T. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02663-z · Cited by 29
Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice
Wang, Z., Jacobus, E. J., Stirling, D. C., Krumm, S. A., Flight, K. E., Cunliffe, R. F., Mottl, J., Singh, C., Mosscrop, L. G., Santiago, L. A., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102045 · Cited by 30
Self-citationAdvances in Nonviral mRNA Delivery Materials and Their Application as Vaccines for Melanoma Therapy
Neill, B., Romero, A. R., & Fenton, O. S. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00721 · Cited by 31
Boros, G., Mikó, E., Muramatsu, H., Weissman, D., Emri, E., Rózsa, D., Nagy, G., Juhász, A., Juhász, I., van der Horst, G. T. J., et al. (2013) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2013.09.010 · Cited by 28
Self-citationPolymeric Nanocarriers for siRNA Delivery: Challenges and Future Prospects
Cun, D., Jensen, L., Nielsen, H. M., Moghimi, S. M., & Foged, C. (2008) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2008.328 · Cited by 28
The European Regulatory Environment of RNA-Based Vaccines
Hinz, T., Kallen, K., Britten, C. M., Flamion, B., Granzer, U., Hoos, A., Huber, C., Khleif, S. N., Kreiter, S., Rammensee, H., et al. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6481-9_13 · Cited by 30
Aligned Nanofibrillar Scaffolds for Controlled Delivery of Modified mRNA
Zaitseva, T. S., Alcazar, C. A., Zamani, M., Hou, L., Sawamura, S. J., Yakubov, E., Hopkins, M., Woo, Y.-P. J., Paukshto, M. V., & Huang, N. F. (2018) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0494 · Cited by 27
Rho proteins are negative regulators of TLR2, TLR3, and TLR4 signaling in astrocytes
Borysiewicz, E., Fil, D., & Konat, G. W. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21968 · Cited by 28
Metadata
- Authors
- Karikó, K., Buckstein, M., Ni, H., & Weissman, D.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Karikó, Katalin
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2005-08
- Volume
- 23
- Issue
- 2
- Pages
- 165-175
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W2025980739
- Cited by
- 2,728
- References
- 35
- Citations by year
- 2026: 319 · 2025: 387 · 2024: 355 · 2023: 323 · 2022: 296 · 2021: 267 · 2020: 86 · 2019: 76 · 2018: 80 · 2017: 58 · 2016: 66 · 2015: 58 · 2014: 48 · 2013: 46 · 2012: 39
- FWCI
- 13.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (AI-50484, AI 060505, R01AI050484, R01AI060505)
- National Institute of Dental and Craniofacial Research (R01DE014825, DE 14825)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Keywords
- Toll-like receptors, RNA recognition, nucleoside modification, TLR3, TLR7, TLR8, m5C, N6-methyladenosine, pseudouridine, dendritic cells, innate immunity, CpG methylation, mitochondrial RNA, bacterial RNA, RNA evolution, cytokine expression
- MeSH terms
- CD83 Antigen, Cell Line, Dendritic Cells, HLA-DR Antigens, Humans, Immunoglobulins, Membrane Glycoproteins, Nucleosides, Phosphatidylethanolamines, Receptors, Cell Surface, RNA, Signal Transduction, Biomarkers, Antigens, CD, Cytokines, Evolution, Molecular, Toll-Like Receptors, Toll-Like Receptor 3, Toll-Like Receptor 7, Toll-Like Receptor 8
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
